TABLE 4.

Cox proportional hazard models for risk of overall and anemia-related mortalites in patients with aplastic anemia.

Characteristics	Risk of overall mortality							Risk of anemia-related mortality
	Crude			Adjusted				Crude			Adjusted
	HR	95% CI	p-value	aHR	95% CI	p-value		HR	95% CI	p-value	aHR	95% CI	p-value
Age (years old)	—	—	—	—	—	—	—		—	—	—	—	—
18≦Age<40 (vs. 0≦Age<18)	2.22	(1.75–2.81)	<0.001	2.54	(2.01–3.20)	<0.001	0.86		(0.37–1.98)	0.722	1.03	(0.44–2.41)	0.948
40≦Age<65 (vs. 0≦Age<18)	4.40	(3.58–5.41)	<0.001	4.11	(3.34–5.06)	<0.001	0.58		(0.28–1.18)	0.130	0.85	(0.40–1.82)	0.681
65≦Age (vs. 0≦Age<18)	6.26	(5.10–7.68)	<0.001	6.21	(5.02–7.68)	<0.001	1.80		(0.94–3.46)	0.079	3.47	(1.66–7.27)	<0.001
Female (vs. male)	0.77	(0.72–0.82)	<0.001	0.76	(0.71–0.81)	<0.001	0.69		(0.49–0.99)	0.041	0.73	(0.50–1.06)	0.102
CHM use (vs. non-CHM use)	0.74	(0.71–0.78)	<0.001	0.70	(0.66–0.74)	<0.001	0.49		(0.34–0.70)	<0.001	0.46	(0.32–0.67)	<0.001

CHM, Chinese herbal medicine; IST, immunosuppressive therapy; HR, hazard ratio; aHR, adjusted hazard ratio; 95% CI, 95% confidence interval.

Patients with aplastic anemia (ICD9-CM code: 284).

CHM use was adjusted by age, gender, comorbidities, and usages of immunosuppressive therapy, glucocorticoid usage, haematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy.

Usages of therapies were applied within 1 year before or after the diagnosed date of aplastic anemia.

Significant p-values (p < 0.05) are highlighted in bold italic font.